Nobivac NXT FeLV (--) - Lyophilisate and solvent for suspension for injection
Nobivac NXT FeLV (--) - Lyophilisate and solvent for suspension for injection
Authorised
- Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient
Product identification
Medicine name:
Nobivac NXT FeLV (--) - Lyophilisate and solvent for suspension for injection
Active substance:
- Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient
Target species:
-
Cat
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI06AX
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:Vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Vial of 1 dose + solvent (0.5ml)
- Packaging:Vial (glass), Package_size:Lyophilisate: 25 vials + solvent: 25 vials, Content:Vial of 1 dose + solvent (0.5ml)
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Intervet International B.V.
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 25/08/2026
Maltese (PDF)
Published on: 25/08/2026
Dutch (PDF)
Published on: 25/08/2026
Croatian (PDF)
Published on: 25/08/2026
Italian (PDF)
Published on: 25/08/2026
Finnish (PDF)
Published on: 25/08/2026
French (PDF)
Published on: 25/08/2026
Lithuanian (PDF)
Published on: 25/08/2026
Estonian (PDF)
Published on: 25/08/2026
Polish (PDF)
Published on: 25/08/2026
Norwegian (PDF)
Published on: 25/08/2026
German (PDF)
Published on: 25/08/2026
Hungarian (PDF)
Published on: 25/08/2026
Greek (PDF)
Published on: 25/08/2026
Danish (PDF)
Published on: 25/08/2026
Spanish (PDF)
Published on: 25/08/2026
Czech (PDF)
Published on: 25/08/2026
Icelandic (PDF)
Published on: 25/08/2026
Portuguese (PDF)
Published on: 25/08/2026
Bulgarian (PDF)
Published on: 25/08/2026
Latvian (PDF)
Published on: 25/08/2026
Romanian (PDF)
Published on: 25/08/2026
Slovak (PDF)
Published on: 25/08/2026
Slovenian (PDF)
Published on: 25/08/2026
Swedish (PDF)
Published on: 25/08/2026
